In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sol-Gel Technologies Ltd (SLGL – Research Report), with a price target of $23. The company’s shares closed last Monday at $8.30.
“We have valued Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of $215M for TWIN, assuming a 70% probability of approval, and a $200M valuation for Epsolay, assuming a 90% probability of approval. Sol-Gel’s partnered generic products contribute an aggregate of approximately $80M. The total represents $495M, or a price per share of $23.00, assuming roughly 21.8M fully-diluted shares outstanding as of mid-2020, which factors in exercise of 1.2M options.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -10.7% and a 27.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.
Currently, the analyst consensus on Sol-Gel Technologies Ltd is a Moderate Buy with an average price target of $21.
The company has a one-year high of $11.36 and a one-year low of $5.41. Currently, Sol-Gel Technologies Ltd has an average volume of 21.38K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.